154 related articles for article (PubMed ID: 24983019)
21. Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre.
Islam MM; Topp L; Conigrave KM; White A; Reid SE; Grummett S; Haber PS; Day CA
J Subst Abuse Treat; 2012 Dec; 43(4):440-5. PubMed ID: 22938915
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of harm reduction programs on seroincidence of HIV, hepatitis B and C, and syphilis among intravenous drug users in southwest China.
Ruan Y; Liang S; Zhu J; Li X; Pan SW; Liu Q; Song B; Wang Q; Xing H; Shao Y
Sex Transm Dis; 2013 Apr; 40(4):323-8. PubMed ID: 23486498
[TBL] [Abstract][Full Text] [Related]
23. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D
Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055
[TBL] [Abstract][Full Text] [Related]
24. Doing harm reduction better: syringe exchange in the United States.
Des Jarlais DC; McKnight C; Goldblatt C; Purchase D
Addiction; 2009 Sep; 104(9):1441-6. PubMed ID: 19215605
[TBL] [Abstract][Full Text] [Related]
25. Secondary syringe exchange as a model for HIV prevention programs in the Russian Federation.
Irwin K; Karchevsky E; Heimer R; Badrieva L
Subst Use Misuse; 2006; 41(6-7):979-99. PubMed ID: 16809182
[TBL] [Abstract][Full Text] [Related]
26. The role of needle exchange programs in HIV prevention.
Vlahov D; Junge B
Public Health Rep; 1998 Jun; 113 Suppl 1(Suppl 1):75-80. PubMed ID: 9722812
[TBL] [Abstract][Full Text] [Related]
27. Commentary on Vickerman et al. (2012): Reducing hepatitis C virus among injection drug users through harm reduction programs.
Smith-Spangler CM; Asch SM
Addiction; 2012 Nov; 107(11):1996-7. PubMed ID: 23039752
[No Abstract] [Full Text] [Related]
28. Texas statewide hepatitis C counseling and testing, 2000-2005.
Heseltine G; McFarlane J
Public Health Rep; 2007; 122 Suppl 2(Suppl 2):6-11. PubMed ID: 17542446
[TBL] [Abstract][Full Text] [Related]
29. Drug use settings: an emerging focus for research and intervention.
Kerr T; Kimber J; Rhodes T
Int J Drug Policy; 2007 Jan; 18(1):1-4. PubMed ID: 17689337
[No Abstract] [Full Text] [Related]
30. Measuring effectiveness of needle and syringe exchange programs for prevention of HIV among injecting drug users: Response to Amundsen.
Maher L; Iversen J; Kaldor J
Addiction; 2006 Dec; 101(12):1834-6. PubMed ID: 17156184
[No Abstract] [Full Text] [Related]
31. Positive Health Project.
Farrell J
Newsline People AIDS Coalit N Y; 1998 Jun; ():18-20. PubMed ID: 11367468
[TBL] [Abstract][Full Text] [Related]
32. Needle exchange program attendance and injection risk in Providence, Rhode Island.
Longshore D; Bluthenthal RN; Stein MD
AIDS Educ Prev; 2001 Feb; 13(1):78-90. PubMed ID: 11252456
[TBL] [Abstract][Full Text] [Related]
33. Thinking ethically about needle and syringe programs.
Kleinig J
Subst Use Misuse; 2006; 41(6-7):815-25. PubMed ID: 16809168
[TBL] [Abstract][Full Text] [Related]
34. New York harm reduction educators.
Ruefli T
Newsline People AIDS Coalit N Y; 1998 Jun; ():9-12. PubMed ID: 11367473
[TBL] [Abstract][Full Text] [Related]
35. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
36. 'Social evils' and harm reduction: the evolving policy environment for human immunodeficiency virus prevention among injection drug users in China and Vietnam.
Hammett TM; Wu Z; Duc TT; Stephens D; Sullivan S; Liu W; Chen Y; Ngu D; Des Jarlais DC
Addiction; 2008 Jan; 103(1):137-45. PubMed ID: 18028519
[TBL] [Abstract][Full Text] [Related]
37. A brief intervention for hazardous drinkers in a needle exchange program.
Stein MD; Anderson B; Charuvastra A; Maksad J; Friedmann PD
J Subst Abuse Treat; 2002 Jan; 22(1):23-31. PubMed ID: 11849904
[TBL] [Abstract][Full Text] [Related]
38. Higher HCV antibody prevalence among Indigenous clients of needle and syringe programs.
Ward J; Topp L; Iversen J; Wand H; Akre S; Kaldor J; Maher L
Aust N Z J Public Health; 2011 Oct; 35(5):421-6. PubMed ID: 21973248
[TBL] [Abstract][Full Text] [Related]
39. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users.
Vassilev ZP; Hagan H; Lyubenova A; Tomov N; Vasilev G; Krasteva D; Des Jarlais DC
Int J STD AIDS; 2006 Sep; 17(9):621-6. PubMed ID: 16942654
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004.
Falster K; Kaldor JM; Maher L;
J Urban Health; 2009 Jan; 86(1):106-18. PubMed ID: 18979201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
